Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Every now and then, it pays to screen the S&P/ASX 200 Index (ASX: XJO) for the worst performers over the past year and check whether they've been oversold and now represent good value.

In the case of the three companies I'm looking at today, brokers have bullish price targets on each, with two of them tipped to more than double over the next 12 months.

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.

Image source: Getty Images

US critical minerals play could pay off

The first of these, and one which appears to have cornered a pretty lucrative niche, is IperionX Ltd (ASX: IPX).

The company is still in the ramp-up phase, albeit close to the end of that period.

Its business is producing aerospace-quality titanium powder at its facility in the US, and then turning that into products to sell.

The company, in its September Quarter report released on 29 October, said it's closing in on its commercial goals.

IperionX said:

With titanium powder capacity validated and inventory established, downstream manufacturing and near-term commercial program execution are now the operational priorities, supported by increased customer qualification.

The company is also developing the Titan critical minerals mining project in the US and completed a definitive feasibility study in June, which outlined a 14-year mine life generating US$1.9 billion in free cash flow.

I'm impressed by the company's close ties with the US defence administration, and the fact that it has US$63 million in cash gives confidence it can fund its operations until it starts generating revenue.

Bell Potter has a price target of $5.60 on IperionX shares compared with $1.77 at the time of writing.

IperionX shares are down 62.9% over the past 12 months.

Major lithium project on the cards

Second cab off the rank is Vulcan Energy Resources Ltd (ASX: VUL), which has experienced a 79% share price slide over the past year.

The company broke ground at its project in Europe in recent days, and it's aiming to start extracting lithium from brine in 2028.

Vulcan has a big capital expenditure task ahead of it, with phase one of its project estimated to cost €1476 million, but it is also backed by major European investors and Gina Rinehart's Hancock Prospecting.

Bell Potter has a $4.50 price target on the company, compared with $1.07 at the time of writing.

High grade iron ore project completes investment phase

And finally there's Champion Iron Ltd (ASX: CIA), which has experienced a 66.8% share price fall over the past year.

Champion is a bit different from most iron ore producers in that it produces a Direct Reduction Pellet Feed (DRPF), which is high grade and fetches a premium price.

The company has spent much of the past year bringing its DRPF operations up to scale, and UBS said in a research note published on 18 November that "management sees a pathway to margin recovery through 2027 via higher DRPF volumes, improved product premiums, lower freight exposure and site-level cost initiatives''.

UBS said the key question was whether the company could maintain quality and output, and realise higher pricing.

The broker has a price target of $3.10 on Champion shares, compared with $1.72 at the time of writing.    

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

2 ASX shares tipped to grow up to 122% in the next 12 months

These companies could be on the cusp of something big.

Read more »

Thumbs down Facebook icon over dark screen.
Broker Notes

Why these 5 ASX shares were downgraded by brokers this week

Market analysts explain why they've downgraded these ASX stocks.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

Buy, hold, sell: Domino's Pizza, Super Retail, PLS shares

Let's check out some new ratings on ASX shares today.

Read more »

Smiling woman taking a video through a plane window with her phone.
Broker Notes

Qantas or Virgin shares. Which ASX airline has more upside?

Will either share take off soon?

Read more »

A little girl wearing wonky glasses checks out what's happening in the world on a mobile phone.
Broker Notes

Buy, hold, sell: Paladin Energy, Accent, Sigma Healthcare shares

Experts reveal the reasons behind their new ratings.

Read more »

A woman looks excited as she fans out a wad of Aussie $100 notes.
Broker Notes

Macquarie predicts 90% upside and an 8% dividend yield for this ASX share

If the broker is right, this share will pay off nicely.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »